Correction to : Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO) (Dermatology and Therapy, (2024), 14, 6, (1479-1493), 10.1007/s13555-023-01086-9)
Pinter, Andreas (University Hospital of Frankfurt (Alemanya))
Costanzo, A. (Dermatology IRCCS Humanitas Research Hospital)
Khattri, S. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Smith, S.D. (The Australian National University)
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Tada, Y. (Teikyo University School of Medicine)
Riedl, E. (Medical University of Vienna)
Reich, A. (Medical College of Rzeszow University)
Brnabic, A. (Eli Lilly and Company)
Haustrup, N. (Eli Lilly and Company)
Lampropoulou, A. (Eli Lilly and Company)
Lipkovich, I. (Eli Lilly and Company)
Kadziola, Z. (Eli Lilly and Company)
Paul, C. (Université Paul Sabatier Toulouse III)
Schuster, C. (Eli Lilly and Company)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	The authors would like to share the following corrections to their publication: The email address of the corresponding author was updated to "andreas. pinter@pinter-med. com". On page 1, the words 'Clinicaltrial. gov identifier' were removed. In the Introduction, the word 'prospective' was added to describe PSoHO. In relation to super responders, the word 'weight' was removed and the incorrect citations of 13-15 were corrected. Mastorino L, Susca S, Cariti C, et al. "Superresponders" at biologic treatment for psoriasis: a comparative study among IL17 and Il23 inhibitors. Exp Dermatol. 2022;32:2187-8. Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, et al. Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life. 2022;12:1412. Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 37(10):2016-27. The layout of Table 1 was updated for clarity and the statistical appendix is now provided. (Table presented. ) Outcomes Definition Primary outcome Patients who achieved (a) At least a 90% improvement in the PASI score (PASI90), or (b) A score of 0 or 1 in sPGA, or (c) Both outcomes PASI100 Patients who achieved 100% improvement in the PASI score PASI90 Patients who achieved at least a 90% improvement in the PASI score DLQI (0,1) Patients with an available DLQI score of 2 or greater at baseline and who subsequently achieved a DLQI score of 0 or 1 Durability of effectiveness outcome Patients who met the primary outcome at week 12 and who subsequently at months 6 and 12 achieved an improvement of (a) At least a 75% in PASI score (PASI75), or (b) 2 or more points in sPGA score from baseline, or (c) Both outcomes PASI100 durability outcome Patients who achieved PASI100 at week 12 and then maintained PASI100 at both months 6 and 12 PASI90 durability outcome Patients who achieved PASI90 at week 12 and then maintained at least PASI90 at both months 6 and 12 The original article has been corrected.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Dermatology and Therapy, Vol. 14 Núm. 6 (6 2024) , p. 1495-1496, ISSN 2190-9172

Article original: https://ddd.uab.cat/record/307489?ln=ca
Erratum: https://ddd.uab.cat/record/311651?ln=ca
DOI: 10.1007/s13555-024-01105-3
PMID: 38814435

2 p, 166.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats